Michael D. Karol

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Daniel J. DeAngelo, Richard M. Stone, Mark Heaney et al. · Blood · 2006 · 275 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care †

R.M. Venn, Michael D. Karol, RM Grounds · British Journal of Anaesthesia · 2002 · 240 citations

Medicine, Anesthesiology, Pharmacokinetics +14

Clinical Sevoflurane Metabolism and Disposition

Evan D. Kharasch, Andrew S. Armstrong, Kerry Gunn et al. · Anesthesiology · 1995 · 177 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Influence of Cardiac Output on Dexmedetomidine Pharmacokinetics

Sandeep Dutta, Ritu Lal, Michael D. Karol et al. · Journal of Pharmaceutical Sciences · 2000 · 120 citations

Medicine, Pharmacokinetics, Pharmacology +10

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

Jonathan W. Goldman, Robert N. Raju, Gregory Gordon et al. · BMC Cancer · 2013 · 116 citations · Full text

Medicine, Oncology, Pharmacology +15